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INTRODUCTION 
Chronic lower back pain (CLBP) is prevalent worldwide in all 
age groups, and is associated with significant morbidity and 
high health care costs.1,2 CLBP treatments are multimodal, in-
cluding medication, injection, physical therapy, exercise, back 
school, and sometimes surgery.3 Since surgical intervention is 
a last resort for CLBP, therapeutic treatment is acute and also 
requires patient adherence. Single or cocktail medical treat-
ments with or without narcotics are conservative, widely ac-
cepted treatment practices. Nonsteroidal anti-inflammatory 
drugs (NSAIDs) are more often prescribed than muscle relax-
ants, antidepressants, antiepileptics, or narcotics.4 
NSAIDs have many side effects, including adverse gastroin-
testinal effects, cardiovascular risk, and patient adherence.5,6 
Cyclooxygenase-2 (COX-2) inhibitors are associated with fewer 
NSAID-related side effects. First-line COX-2 inhibitors are rec-
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ommended for elderly patients presenting with osteoarthritis 
and gastrointestinal risk factors. Conventional NSAIDs can be 
prescribed to relatively young patients (<60 years) with mus-
culoskeletal pain, in whom cardiovascular and gastrointesti-
nal risk is relatively lower than patients >60 years. 
Aceclofenac is a NSAID phenylacetic acid derivative {2-[(2, 
6-dichlorophenyl)amino]-phenylacetoxyacetic acid} widely 
and safely prescribed for musculoskeletal pain associated 
with rheumatic, degenerative, and traumatic injury etiologies.7-9 
Furthermore, aceclofenac is effective for managing acute to 
CLBP, and has a wide safety profile.10 Aceclofenac and diclofe-
nac are classified as acetic acid NASIDs, and are not associat-
ed with adverse cardiovascular events. NSAIDs that have been 
associated with adverse cardiovascular events include ibupro-
fen, celecoxib, and rofecoxib.11
Dose interval is a crucial factor to assuring adherence to 
medical therapy. Increased dose interval has been associated 
with increased patient adherence to NSAID and osteoporotic 
medication.12 Controlled release (CR) maintained therapeutic 
serum levels for longer periods of time, with less gastrointesti-
nal insult and increased patient adherence.13
Accordingly, the purpose of this clinical trial was to compare 
the efficacy and safety of a once daily dose of aceclofenac CR 
and a twice daily dose of aceclofenac for CLBP management. 
MATERIALS AND METHODS
Study design
A prospective, randomized, single center, open-label clinical 
trial was performed from February 2011 to December 2012 at 
an out-patient orthopedic clinic. The clinical trial protocol was 
approved by the Institutional Review Board of Yonsei Univer-
sity College of Medicine, Seoul, Korea (CR NO. 4-2010-0433). 
All subjects voluntarily submitted informed consent after thor-
ough trial protocol explanation. The trial protocol was devel-
oped to compare the efficacy and safety of a once daily dose of 
aceclofenac CR (200 mg once daily) to a conventional twice 
daily aceclofenac dose (100 mg twice daily) (Fig. 1). Change in 
Visual Analogue Scale (VAS) (range 0–100; higher scores indi-
cate greater pain)14 from baseline to 2 weeks after each medi-
cation was assessed. Safety profiles, change in quality of life as 
measured by EuroQoL 5D (EQ-5D),15,16 and Oswestry Disability 
Index (ODI)17,18 functional score for lumbar spine were also 
assessed. Data were analyzed with an intention-to-treat design.
The sample size calculation was based on differences in VAS 
score between the groups as obtained from a previous study.13 
We calculated that a minimum of 45 patients would be needed 
in each treatment arm (allowing 20% dropouts) to detect a dif-
ference of at least 0.6 between groups with a two-sided type I 
error of 0.05 and 80% power. 
Subject selection criteria
Inclusion criteria
Subjects of both genders aged 20 to 75 years reporting CLBP 
for at least 3 months or more, with pain intensity as measured 
by the VAS >40 mm, were enrolled. CLBP pain parameters in-
cluded lower back pain >3 months, VAS >40 mm, CLBP with 
or without leg pain, daily pain attacks, and persistent pain. 
Plain lumbar radiographs were used to make diagnoses. De-
tailed procedures and hazard/benefit were carefully explained 
to all subjects. 
Exclusion criteria
Subjects were excluded if they presented with acute fracture, 
malignancy, neurologic deficit, severe leg pain mandating sur-
gery (lumbar disc herniation and spinal stenosis), fibromyalgia, 
compensation case, recent injection procedure, spinal surgery, 
history of allergy to aceclofenac, narcotic abuse, and alcohol 
abuse. 
Outcome measures
Visual Analogue Scale 
VAS mean level of back pain was assessed (0–100 mm pain 
scale: 0=none and 100=unbearable).
EQ-5D
EQ-5D consisted of five dimensions: mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression. Each di-
mension had three levels of severity: 1) no problems, 2) some 
problems, and 3) extreme problems. EQ-5D was calculated 
thusly: each level of all dimensions with 1 as perfect, and 0 as 
worst quality of life. Current general health status was also as-
sessed using the EQ-5D VAS (0–100, 100=best health status). 
Oswestry Disability Index
The ODI is a 10-item self-report questionnaire measuring 
“back-specific function” with six response levels. Each item 
was scored from 0 to 5, higher scores being worse, which were 
transformed into a 0 to 100 scale. The 10 items included pain 
intensity, personal care, lifting, walking, sitting, standing, sleep-
ing, sex life, social life, and traveling.
Table 1. Patient Demographic Data
Aceclofenac CR Aceclofenac p value
Number of patients (n) 50 50
Gender (male:female) 12:38 12:38 1.000*
Age 57.6±11.3 56.9±11 0.799†
Height (cm) 160.2±8.1 159.6±7.7 0.695†
Weight (kg) 62.3±8.7 61.6±8.7 0.978†
Duration of back pain 50.0±55.1 91.6±119.0 0.184†
CR, controlled release.
*Chi-square test, †Unpaired t-test.
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Gastrointenstinal assessment
A separate questionnaire was utilized to assess post-treatment 
gastrointestinal symptoms. The following six items were in-
cluded: indigestion, heartburn, nausea, vomiting, abdominal 
pain, and diarrahea graded as 1, 2, or 3 (minimal to severe symp-
toms limiting daily activities). 
Statistical analysis
Values of VAS and EQ-5D VAS are expressed as mean with 
standard deviation, and values of EQ-5D and ODI are ex-
pressed as median with an inter-quartile range (IQR). To com-
pare pain reduction in VAS and change in EQ-5D VAS after 
treatment, paired t-test was utilized. Quality of life improve-
ment as EQ-5D and ODI were analyzed by using non-para-
metric statistics, such as Mann-Whitney U test, to compare 
changes in EQ-5D and ODI pre-and post-treatment in each 
group and Wilcoxon’s rank sum test to compare changes in 
EQ-5D and ODI between aceclofenac CR and aceclofenac 
groups. To compare gastrointestinal symptoms and adverse ef-
fects between groups, Fisher’s exact test was used. Significance 
level was set as p<0.05.
RESULTS
Of 106 subjects screened with the criteria described above, 100 
Table 2. Change of Pain in VAS, EQ-5D, EQ-5D VAS, and ODI
100-mm VAS score
Aceclofenac CR (n=50)
In group
Aceclofenac (n=50)
In group Between group
Mean±SD Mean±SD
Pre treat 58.2±14.0 64.0±13.1 p=0.075†
Post treat 35.7±17.1 p=0.028* 45.5±20.8 p=0.013* p=0.109†
Alteration 22.6±15.8 18.6±17.7 p=0.145†
EQ-5D VAS
Aceclofenac CR (n=20)
In group
Aceclofenac (n=20)
In group Between group
Mean±SD Mean±SD
Pre treat 60.0±15.1 62.7±14.1† p=0.245†
Post treat 65.0±22.5 p=0.071* 68.5±13*† p=0.082* p=0.125†
Alteration 5.0±14.7 5.8±16.7 p=0.249†
EQ-5D
Aceclofenac CR (n=50)
In group
Aceclofenac (n=50)
In group Between group
Median (IQR) Median (IQR)
Pre treat 0.5 (0.3–0.7) 0.5 (0.3–0.7) p=0.423§
Post treat 0.7 (0.5–0.9) p=0.037‡ 0.6 (0.4–0.8) p=0.042‡ p=0.359§
Alteration 0.2 (0.1–0.4) 0.1 (-0.1–0.3) p=0.438§
ODI
Aceclofenac CR (n=50)
In group
Aceclofenac (n=50)
In group Between group
Median (IQR) Median (IQR)
Pre treat 34.6 (21.8–47.4) 37.1±13.3 (23.8–50.4) p=0.097§
Post treat 23.8 (11.1–36.5) p=0.012‡ 27.3±12.7 (14.6–40.0) p=0.026‡ p=0.165§
Alteration 10.6 (-1.0–22.2) 10.4±12.9 (-2.5–23.3) p=0.581§
CR, controlled release; VAS, Visual Analogue Scale; EQ-5D, EuroQoL 5D; EQ-5D VAS, EuroQoL 5D Visual Analogue Scale; ODI, Oswestry Disability Index.
Values of VAS and EQ-5D VAS are expressed as mean with standard deviation (SD). Values of EQ-5D and ODI are expressed as median with an inter-quartile 
range (IQR) in parenthesis. p<0.05: statistically significant.
*Paired t-test: to compare VAS, EQ5D VAS of pre- and post-treatment in each group, †Unpaired t-test: to compare VAS, EQ5D VAS between aceclofenac CR and 
aceclofenac groups, ‡Mann-Whitney U test: to compare EQ-5D, ODI change of pre-and post-treatment in each group, §Wilcoxon signed rank test: to compare EQ-5D, 
ODI change between aceclofenac CR and aceclofenac groups.
Fig. 1. Screening, randomization, and follow-up of clinical trial. CR, con-
trolled release.
Discontinuation
(n=3, 6%)
Withdrew consent
Aceclofenac CR (n=50)
Randomization (n=100)
Screening (n=106)
Completed study
(n=47, 94%)
Aceclofenac (n=50)
Completed study
(n=50, 100%)
Table 3. Gastrointenstinal Symptom Assessment
Gastrointestinal 
symptom
Aceclofenac CR  
(n=47)
Aceclofenac
 (n=50)
p value
Indigestion, n (%) 4 (8.5) 1 (2.0) 0.195
Heartburn, n (%) 10 (21.3) 3 (6.0) 0.037
Nausea, n (%) 2 (4.3) 1 (2.0) 0.610
Vomit, n (%) 1 (2.1) 0 (0.0) 0.485
Abdominal pain, n (%) 2 (4.3) 0 (0.0) 0.232
Diarrahea, n (%) 1 (2.1) 0 (0.0) 0.485
CR, controlled release.
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subjects were assigned to either aceclofenac CR (200 mg once 
daily) or conventional aceclofenac (100 mg twice daily) groups. 
There were 50 subjects in each group. During the study, only 
three subjects from the aceclofenac CR group dropped out of 
the study; all 50 aceclofenac subjects completed the study. 
Before treatment, there were no differences between groups 
in demographic characteristics, duration of lower back pain, 
VAS, EQ-5D, or ODI (Table 1 and 2).
Table 4. Adverse Events
System organ class
Preferred term
p valueAceclofenac CR (n=50) Aceclofenac (n=50)
Adverse events Adverse events
Gastrointestinal disorders, n (%) 10 (21.2) 7 (14.0) 0.595
Dyspepsia 10 (21.2) 4 (8.0)
Nausea 2 (4.2) 1 (2.0)
Constipation 2 (4.2) 0 (0.0)
Abdominal pain 2 (4.2) 0 (0.0)
Abdominal distension 0 (0.0) 2 (4.0)
Vomiting 1 (2.1) 0 (0.0)
Diarrhea 1 (2.1) 0 (0.0)
Skin and subcutaneous tissue disorders, n (%) 5 (10.6) 5 (10.0) >0.999
Swelling face 3 (6.4) 3 (6.0)
Pruritus 1 (2.1) 1 (2.0)
Skin disorder 1 (2.1) 0 (0.0)
Acne 0 (0.0) 1 (2.0)
General disorders and administration site conditions, n (%) 9 (19.2) 1 (2.0) 0.016
Generalized edema 5 (10.6) 0 (0.0)
Swelling 1 (2.1) 1 (2.0)
Edema peripheral 1 (2.1) 0 (0.0)
Edema 1 (2.1) 0 (0.0)
Face edema 1 (2.1) 0 (0.0)
Nervous system disorders, n (%) 3 (6.4) 4 (8.0) >0.999
Somnolence 2 (4.3) 1 (2.0)
Paresthesia 0 (0.0) 2 (4.0)
Dizziness 0 (0.0) 1 (2.0)
Headache 1 (2.1) 0 (0.0)
Investigations, n (%) 0 (0.0) 4 (8.0) 0.117
Aspartate aminotransferase increased 0 (0.0) 2 (4.0)
Gamma-glutamyltransferase increased 0 (0.0) 2 (4.0)
Alanine aminotransferase increased 0 (0.0) 1 (2.0)
Infections and infestations, n (%) 1 (2.1) 1 (2.0) >0.999
Nasopharyngitis 0 (0.0) 1 (2.0)
Oral herpes 1 (2.1) 0 (0.0)
Musculoskeletal and connective tissue disorders, n (%) 2 (4.3) 0 (0.0) 0.495
Pain in extremity 1 (2.1) 0 (0.0)
Musculoskeletal pain 1 (2.1) 0 (0.0)
Vascular disorders, n (%) 1 (2.1) 0 (0.0) >0.999
Flushing 1 (2.1) 0 (0.0)
Renal and urinary disorders, n (%) 1 (2.1) 0 (0.0) >0.999
Pollakiuria 1 (2.1) 0 (0.0)
Eye disorders, n (%) 0 (0.0) 1 (2.0) >0.999
Abnormal sensation in eye 0 (0.0) 1 (2.0)
Cardiac disorders, n (%) 1 (2.1) 0 (0.0) >0.999
Palpitations 1 (2.1) 0 (0.0)
CR, controlled release.
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VAS (0–100 mm) pain intensity was significantly reduced in 
both groups: aceclofenac CR, before 58.2±14.0, after 35.7±17.1, 
p<0.05; aceclofenac, before 64.0±13.1, after 45.5±20.8, p<0.05. 
There was no significant difference in pain intensity between 
groups pre- and post-treatment (Table 2, Fig. 2A).
Quality of life as measured by calculated EQ-5D increased 
significantly in aceclofenac CR [before 0.5 (0.3–0.7), after 0.7 
(0.5–0.9), p<0.05] and aceclofenac groups [before 0.5 (0.3–0.7), 
after 0.6 (0.4–0.8), p<0.05]. By contrast, there were no signfi-
cant differences in EQ-5D general health status between ace-
clofenac CR and aceclofenac groups pre- and post-treatment. 
All EQ-5D dimensions (mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression), except self-care in 
the aceclopenac group, showed level increases (Table 2, Figs. 
2B and 3). 
ODI spinal functional score decreased significantly in both 
aceclofenac CR [before 34.6 (21.8–47.4), after 23.8 (11.1–36.5), 
p<0.05] and aceclofenac groups [before 37.1±13.3 (23.8–50.4), 
after 27.3±12.7 (14.6–40.0), p<0.05]. In contrast, there was no 
signficant difference between groups for other ODI items pre- 
and post-treatment (Table 2, Fig. 2C).
Gastrointenstional assessment revealed the aceclofenac CR 
group presented with more complaints than the aceclofenac 
group for all items: indigestion (4 vs. 1), heartburn (10 vs. 3) 
(p<0.05), nausea (2 vs. 1), vomiting (1 vs. 0), abdominal pain (2 
vs. 0), and diarrahea (1 vs. 0). Among items of gastrointenstion-
al assessment, only heartburn showed significant increase in 
aceclofenac CR group (p<0.05). However, the aceclofenac CR 
group presented only five complaints at the most severe symp-
tom level, while the remaining 15 were at minimal and tolera-
ble levels (Table 3).
Adverse effects post aceclofenac CR and aceclofenac treat-
ment are presented in Table 4. In mutiple categories (gastro-
intestinal, skin and subcutaneous, general physical, nervous 
system, serologic, infectious, musculoskeletal, vascular, renal, 
ocular, and cardiac) there were no significant differences in 
adverse effects between groups, except edema and swelling in 
general disorders and administration site conditions (p<0.05).
DISCUSSION
Both aceclofenac CR and aceclofenac were associated with 
significant pain reduction, increase in quality of life, improve-
ment in spinal function, and tolerable minor adverse effects. 
For all measures only EQ-5D VAS showed no significant change 
pre- to post-treatment. 
There was significant VAS reduction for aceclofenac CR 
(22.6) and aceclofenac (18.6), which was significant within 
groups pre- and post-treatment; however, there was no signif-
icant difference between groups pre- and post-treatment. Fur-
thermore, increase in quality of life as calculated by EQ-5D was 
also significant within both groups. Alpha was set at 0.05, but 
p=0.10 for EQ-5D increase for both groups. Also, both groups 
showed significant improvement in ODI spinal functional 
score. There was no significant difference between groups in all 
ODI categories. A questionnaire specifically assessing gastro-
intestinal symptoms showed increased overall gastrointestinal 
complaints in both groups: aceclofenac CR (19 complaints) 
and aceclofenac (5 complaints). However, rate of heartburn 
was statistically significantly higher in the aceclofenac CR 
group. This protocol did not provide any gastrointestinal medi-
cations to protect stomach and duodenum mucosa, hence a 
single daily dose of aceclofenac CR (200 mg) might result in 
greater acidic insult to gastric mucosa than the lower twice 
daily dose (100 mg). There were no serious gastrointestinal ef-
fects seen in either group during the study interval. Among gas-
trointestinal complaints (20 incidences) on a questionnare spe-
cilized for gastrointestinal symptoms in the aceclopenac CR 
group, only five complaints were severe in intensity, while the 
Fig. 2. (A) Change in Visual Analogue Scale (VAS) presented as mean±standard deviation. (B) Change in calculated EuroQoL 5D (EQ-5D) presented as 
median and interquartile range (IQR). (C) Change in Oswestry Disability Index (ODI), presented as median and IQR. Comparison between aceclofenac 
controlled release (CR; 200 mg once daily) and conventional aceclofenac (100 mg twice daily) showed there was significant reduction of pain and ODI 
score, and increase in EQ-5D for each group at 2 weeks, however, there was no difference between groups pre- and post-treatment for VAS, ODI, and 
EQ-5D. *p<0.05, †Non-significant.
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remaning 15 complaints were minial intensity. Even though pa-
tients were enrolled in randomized fashion, duration of CLBP 
is different between aceclofenac CR and aceclofenac. Since 
CLBP is defined as lower back pain for more than 3 months, 
several outliers, such as CLBP more than years, seem to provide 
differences between groups. However, the duration of CLBP 
between group was statistically insignificant and chronicity of 
lower back pain seemed to have little effect on aceclofenac in-
tervention, as shown in the results of uniform improvement in 
pain scale and quality of life measurements.
In conclusion, this prospective, randomized, single center, 
open-level aceclofenac CR and aceclofenac clinical trial in sub-
jects with CLBP showed both dose regimens resulted in effec-
tive symptomatic pain relief, improvement in quality of life and 
functional scores, and tolerable adverse gastrointestinal effects.
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